Evoke Pharma Operating Income 2012-2024 | EVOK

Evoke Pharma operating income from 2012 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Evoke Pharma Annual Operating Income
(Millions of US $)
2023 $-7
2022 $-8
2021 $-8
2020 $-13
2019 $-7
2018 $-8
2017 $-11
2016 $-11
2015 $-12
2014 $-13
2013 $-3
2012 $-2
2011 $-2
Evoke Pharma Quarterly Operating Income
(Millions of US $)
2024-06-30 $-1
2024-03-31 $-2
2023-12-31 $-2
2023-09-30 $-2
2023-06-30 $-2
2023-03-31 $-2
2022-12-31 $-2
2022-09-30 $-2
2022-06-30 $-2
2022-03-31 $-2
2021-12-31 $-2
2021-09-30 $-2
2021-06-30 $-2
2021-03-31 $-3
2020-12-31 $-2
2020-09-30 $-2
2020-06-30 $-7
2020-03-31 $-2
2019-12-31 $-1
2019-09-30 $-2
2019-06-30 $-2
2019-03-31 $-2
2018-12-31 $-2
2018-09-30 $-2
2018-06-30 $-2
2018-03-31 $-2
2017-12-31 $-3
2017-09-30 $-4
2017-06-30 $-3
2017-03-31 $-2
2016-12-31 $-2
2016-09-30 $-2
2016-06-30 $-3
2016-03-31 $-3
2015-12-31 $-3
2015-09-30 $-3
2015-06-30 $-3
2015-03-31 $-3
2014-12-31 $-3
2014-09-30 $-4
2014-06-30 $-3
2014-03-31 $-3
2013-12-31 $-2
2013-09-30 $-0
2013-06-30 $-0
2013-03-31 $-0
2012-12-31
2012-09-30 $-0
2012-06-30
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.005B $0.005B
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Teligent (TLGT) United States $0.000B 0.00